Sicard, G.; Paris, C.; Giacometti, S.; Rodallec, A.; Ciccolini, J.; Rocchi, P.; Fanciullino, R.
Enhanced Antisense Oligonucleotide Delivery Using Cationic Liposomes Grafted with Trastuzumab: A Proof-of-Concept Study in Prostate Cancer. Pharmaceutics 2020, 12, 1166.
https://doi.org/10.3390/pharmaceutics12121166
AMA Style
Sicard G, Paris C, Giacometti S, Rodallec A, Ciccolini J, Rocchi P, Fanciullino R.
Enhanced Antisense Oligonucleotide Delivery Using Cationic Liposomes Grafted with Trastuzumab: A Proof-of-Concept Study in Prostate Cancer. Pharmaceutics. 2020; 12(12):1166.
https://doi.org/10.3390/pharmaceutics12121166
Chicago/Turabian Style
Sicard, Guillaume, Clément Paris, Sarah Giacometti, Anne Rodallec, Joseph Ciccolini, Palma Rocchi, and Raphaëlle Fanciullino.
2020. "Enhanced Antisense Oligonucleotide Delivery Using Cationic Liposomes Grafted with Trastuzumab: A Proof-of-Concept Study in Prostate Cancer" Pharmaceutics 12, no. 12: 1166.
https://doi.org/10.3390/pharmaceutics12121166
APA Style
Sicard, G., Paris, C., Giacometti, S., Rodallec, A., Ciccolini, J., Rocchi, P., & Fanciullino, R.
(2020). Enhanced Antisense Oligonucleotide Delivery Using Cationic Liposomes Grafted with Trastuzumab: A Proof-of-Concept Study in Prostate Cancer. Pharmaceutics, 12(12), 1166.
https://doi.org/10.3390/pharmaceutics12121166